ReviewMarine drugs2020
Molecular Targets and Related Biologic Activities of Fucoidan: A Review.
Review in Marine drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Effects of Ingesting Fucoidan Derived fromMarine drugs · 2021Trial
- Biopolymer Surface Modification as a Strategy for Conferring "Stealth-like" Characteristics of Xanthohumol-Loaded Liposomes.Polymers · 2026Article
- Marine Bioactives in Liver Aging: Mechanistic Insights and Translational Potential.Marine drugs · 2026Review
- From Sea to Sight: Fucoidan Protects Against Oxidative Damage in Porcine Retina Organ Culture.Marine drugs · 2026Article
- Sclerostin in Vascular Calcification: Hypoxia-Driven Regulation and Therapeutic Modulation by Natural Products.Current atherosclerosis reports · 2026Review
- Advancements in dual-targeting nanoparticle strategies for enhanced atherosclerosis therapy: Overcoming limitations of single-targeting approaches.Bioactive materials · 2026Review
- Chromosome-scale genome assembly and annotation of Saccharina sculpera.Scientific data · 2025Article
- Nasal Administration ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Targeted nanomedicines for the treatment ofMaterials today. Bio · 2025Review
- DNA Dendron Tagging as a Universal Way to Deliver Proteins to Cells.Journal of the American Chemical Society · 2025Article
- Marine-Derived Fucose-Containing Carbohydrates: Review of Sources, Structure, and Beneficial Effects on Gastrointestinal Health.Foods (Basel, Switzerland) · 2024Review
- In Vitro Anti-HIV-1 Activity of Fucoidans from Brown Algae.Marine drugs · 2024Article
- Specific interaction between Group BInfection and immunity · 2024Article
- Review
- Biopolymer-Based Nanomedicine for Cancer Therapy: Opportunities and Challenges.International journal of nanomedicine · 2024Review
- Fucoidan's Molecular Targets: A Comprehensive Review of Its Unique and Multiple Targets Accounting for Promising Bioactivities Supported by In Silico Studies.Marine drugs · 2023Review
- Atheroprotective Effect of Fucoidan in THP-1 Macrophages by Potential Upregulation of ABCA1.Biomedicines · 2023Article
- Anti-International journal of molecular sciences · 2023Article
- Fucoidan-Derived Functional Oligosaccharides: Recent Developments, Preparation, and Potential Applications.Foods (Basel, Switzerland) · 2023Review
- Gene Set Enrichment Analysis Reveals That Fucoidan Induces Type I IFN Pathways in BMDC.Nutrients · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Fucoidan-a marine natural active polysaccharide derived from brown algae with a variety of medicinal activities and low toxicity-has been used as clinical drug for renal diseases for nearly 20 years. The pharmacological mechanism of fucoidan has been well-investigated, based on target molecules and downstream signaling pathways. This review summarizes some important molecular targets of fucoidan and its related biologic activities, including scavenger receptor (SR), Toll-like receptors (TLRs), C-type lectin (CLEC) and some newly found target molecules, which may be beneficial for further understanding the pharmacological mechanism of fucoidan and discovering its new functions, as well as developing related clinical or adjuvant drugs and functional preparations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.